Protein Expression Market (2025-2032)
Protein Expression Market is projected to reach $5 billion by 2032, at a CAGR of 7.6% from 2025 to 2032.
- Published
- Jan 2025
- Pages
- 270
- Format
- PDF + Excel
- Report ID
- MR-932
- Base year
- 2024
- 2032 · FORECAST
- $5.00B
- 2032
- $5.00B
- CAGR 2025–2032
- 7.6%
2024 baseline · 2025–2032 forecast at 7.6% CAGR · hover a bar for the value
Key highlights
In 2025, the Mammalian Cell Expression System Segment is Expected to Dominate the Market
In 2025, the Reagents Segment is Expected to Dominate the Market
In 2025, the Research Segment is Expected to Exhibit Highest CAGR
In 2025, the Contract Research Organizations Segment is Expected to Exhibit Highest CAGR
Asia-Pacific: Fastest-growing Regional Market
Report summary
| Particulars | Details |
|---|---|
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2025–2032 |
| Market Size (2032) | USD 5.00 billion |
| CAGR (2025–2032) | 7.6% |
| Format | PDF, Excel & Cloud Portal · 270 pages |
| Segments Covered | By System: HEK 293 Cell Lines, Other Mammalian Cell Lines, Bacterial Cell Lines, Insect Cell Lines, Yeast Cell Lines, Plant Cell Lines, Algal-based Cell Lines · By Product & Service: Instruments, Kits & Reagents, Competent Cells Chemically Competent Cells, Electrocompetent Cells · By Application: Therapeutic, Research, Industrial · By End User: Pharmaceutical & Biotechnology Industry, Academic & Research Institutes, Contract Research Organizations (CROs) · By Offering: Kits & Reagents, Vectors, Competent Cells, Services |
| Countries Covered | Europe (RoE) |
| Key Companies | Thermo Fisher Scientific Inc., Promega Corporation, Merck KGaA, Bio-Rad Laboratories, Inc., GenScript Biotech Corporation, Qiagen N.V., Agilent Technologies, Inc., Danaher Corporation |
Report overview
Segments covered: system, product & service, application, end user, offering. Regions: Europe.
Protein expression is the process of synthesizing an unnaturally occurring protein (heterologous protein) by introducing recombinant DNA into the host cell. For this, prokaryotic and eukaryotic are used depending on economic and qualitative aspects, such as the type of protein, function, and desired protein yield. These systems are used for therapeutic, research, or industrial purposes.
The increasing biopharmaceutical market, growing demand for recombinant proteins, rising government initiatives, and funding for life science research are driving the growth of this market. Furthermore, the potential emerging economies are expected to offer significant growth opportunities for the protein expression market.
However, the high cost of protein-based research and the lack of skilled professionals are expected to restrain the growth of this market. Additionally, complexities in laboratory transformation parameters are challenging the growth of this market.
Market dynamics
1 factors across 1 forceEmerging Economies Provide Opportunity for the Players in the Market
Developed economies like the U.S. and European countries have contributed greatly to the biopharmaceutical market. These markets are relatively better penetrated, and thus, players in this market are increasingly shifting their focus to underpenetrated emerging economies. Emerging countries in Asia and Latin America offers high growth opportunities attributed to the growing demand for biopharmaceutical products, increasing aging population suffering from chronic and infectious diseases, rising pharmaceutical R&D expenditure, growing demand for biologics, and growing disposable income.
Rising public & private funding for R&D and rising contract research and manufacturing activities support the biopharmaceutical industry's growth across China, India, and the Association of Southeast Asian Nations (ASEAN) member countries in the Asia-Pacific region, Brazil, and Mexico in Latin America. The rising demand for biopharmaceuticals and growing pressure to curtail the high development cost are compelling the biopharmaceutical industries to outsource research, development, and manufacturing to minimize cost and save time. Due to this, CDMOs in emerging nations are experiencing a high growth rate and are actively involved in the production and development of biopharmaceuticals. This is attributed to growing infrastructure and capacity development investments, low labor costs, improving adherence to global manufacturing standards, and increasing regulatory oversight.
The development of biosimilar therapeutics is gaining pace in developing economies like China and India. China is experiencing a spike in biopharmaceutical development. The Chinese government has undertaken several initiatives to develop and commercialize biosimilars. Some of these initiatives include developing multinational clinical centers and accelerating the approval process for special medicines. The introduction of the Marketing Authorization Holder (MAH) plan to launch biosimilars in China has allowed license holders to sell biosimilars through contract manufacturing.
These initiatives in emerging economies for bioproduction or research provide an opportunity for a higher demand for protein expression systems.
Table of contents
12 chapters · 96 sections · 270 pages · click to expandSegmental analysis
| Segment | Largest share (2025) | Fastest growth (2025–2032) |
|---|---|---|
| By System Type | Mammalian Cell Expression System | — |
| By Products & Service | Reagents | — |
| By Application | — | Research |
| By End User | — | Contract research organizations |
By System Type
- The mammalian cell expression system segment is expected to account for the largest share of this market.
- This segment’s large market share is attributed to advantages like the low risk of cross-contamination, no need for post-translational modification, and wider acceptance for therapeutic applications.
By Products & Service
- The reagents segment is expected to account for the largest share of the protein expression market.
- The large market share of this segment is attributed to factors such as frequent use of them for research, therapeutics, or industrial purposes.
By Application
- The research segment is expected to grow at the highest CAGR in the protein expression market.
- Factors such as a growing R&D expenditure, the emergence of new diseases, and a focus on pharma-academic collaboration for boosting research supported the growth of the market.
By End User
- The contract research organizations segment is expected to exhibit the highest CAGR owing to the growing focus of many vendors on outsourcing and government initiatives for expanding research activities.
Geographic analysis
Asia-Pacific
Fastest growthThe growth of this market is driven by the increasing investments in life science research in developing countries such as China and India, and the growing preference for recombinant technology owing to advantages such as low risk of immune reaction, no interference of protein contaminants, and short production lead times as there is no need of purification process in recombinant technology. Thus, compared to traditional technology, recombinant is driving the growth of the protein expression market in Asia-Pacific. Asia-Pacific: Fastest-growing Regional Market
Competitive landscape
- Thermo Fisher Scientific Inc.
- Promega Corporation
- Merck KGaA
- Bio-Rad Laboratories, Inc.
- GenScript Biotech Corporation
- Qiagen N.V.
- Agilent Technologies, Inc.
- Danaher Corporation
Frequently asked questions
This study offers a detailed assessment of the protein expression market and analyzes the market sizes & forecasts based on system type, product & service, application, and end user. This report also involves the value analysis of various segments and subsegments of the protein expression market at the regional and country levels.
Cite this report
Meticulous Research. (2025). Protein Expression Market - Global Opportunity Analysis and Industry Forecast (2025-2032) (Report No. MR-932). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/reports/protein-expression-market-5615